Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814145 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
A Phase 2 study of Hypertension, Pulmonary, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06814145 is a Phase 2 study of Hypertension, Pulmonary that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 130 participants, below the 732-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06814145, a Phase 2 study of Hypertension, Pulmonary, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time. The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.
Conditions Studied
Interventions
- BIOLOGICAL Sotatercept
Study Locations (20)
Ohio
- The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001) - Cincinnati
- The Cleveland Clinic Foundation. ( Site 1065) - Cleveland
- The Ohio State University Wexner Medical Center ( Site 1032) - Columbus
California
- Jeffrey S. Sager, MD Medical Corporation ( Site 1060) - Santa Barbara
- Stanford University Medical Center ( Site 1024) - Stanford
Pennsylvania
- Allegheny General Hospital ( Site 1088) - Pittsburgh
- Lankenau Medical Center ( Site 1089) - Wynnewood
Arizona
- Pulmonary Associates, PA ( Site 1008) - Phoenix
Colorado
- South Denver Cardiology Associates ( Site 1091) - Littleton
Connecticut
- Yale New Haven Hospital ( Site 1093) - New Haven
Florida
- AdventHealth Orlando ( Site 1058) - Orlando
Georgia
- The Emory Clinic ( Site 1030) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06814145
The ClinicalTrials.gov registry entry for NCT06814145 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 732-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (82% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension, Pulmonary appearing as the primary indexed condition, and to 1 intervention - of which Sotatercept is the first listed.
NCT06814145 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ohio, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06814145 about?
NCT06814145 is a clinical study titled "Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)". Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF). Researchers want to know ...
What is the current status of trial NCT06814145?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-04-16. Estimated completion is 2029-03-30.
What conditions does trial NCT06814145 study?
This clinical trial studies the following conditions: Hypertension, Pulmonary.
What interventions are being tested in trial NCT06814145?
The interventions under investigation include: Sotatercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT06814145?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06814145 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension, Pulmonary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
ACTIVE NOT RECRUITING · Phase 2
-
Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
COMPLETED · Phase 2
-
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
RECRUITING
-
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
ACTIVE NOT RECRUITING · NA
-
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.